Analyst Report: GEHC
1. EXECUTIVE SUMMARY
GE HealthCare rose 6.62% to $75.82 on Wednesday October 28, 2026, after third-quarter results that beat on earnings and came with higher full-year guidance. Adjusted EPS of $1.34 exceeded the Zacks consensus of $1.21 by 10.7%, adjusted EBIT margin reached 16.6%, and management lifted its adjusted EPS range to $4.95–5.05 from $4.80–5.00. Volume of 9,569,300 shares was 2.86 times the 50-session average. Three brokers raised price targets the same day. The shares closed above both the 50-day and 200-day averages, and the move leaves the stock 8.27% lower year to date. Cash flow included a $55m tariff refund, and the brief confirms no cause for the prior session's decline.
2. THE CATALYST
GE HealthCare released third-quarter results on October 28, the day of the move. According to the company press release, revenue rose 7.2% reported and 6.2% organically, orders grew 4.0% organically, book-to-bill was 1.03x and backlog stood at $23.7bn. The CEO said the company is raising full-year guidance and credited commercial execution and operational focus enabled by the Heartbeat program.
Zacks, via Yahoo Finance, reported adjusted EPS of $1.34, up 25.1% year over year, with volumes, pricing, cost productivity and lower net tariff impacts as drivers. Adjusted EBIT rose 19.9% to $913m, and the adjusted margin of 16.6% was up 180 bp.
| Guidance item | New | Prior |
|---|---|---|
| Adjusted EPS | $4.95–5.05 | $4.80–5.00 |
| Organic growth | about 4% | 3–4% |
| Adjusted EBIT margin | 15.5–15.7% | 15.4–15.7% |
| Free cash flow | above $1.6bn | not given in brief |
Source for guidance: Yahoo Finance/IBD-style report, October 28. Operating cash flow was $907m and free cash flow $793m, and the press release shows both include a $55m tariff refund. Per the Yahoo Finance call summary, the quarterly dividend was raised 14%.
Yahoo/IBD reported shares up more than 4% pre-market. Other outlets cite intraday gains of 7.2% and 8.3%, which conflict with each other; the official close of +6.62% is the figure used here.
Consensus figures also conflict. The site's panel lists a revenue estimate of $5.94bn and an EPS estimate of 1.6, while Zacks, Investing.com and Chartmill cite revenue near $5.35bn to $5.46bn and EPS of $1.21 to $1.23. Chartmill described revenue as roughly in line and the beat as profit-led. The EPS beat quoted in this report uses the Zacks figure.
The preceding session, October 27, closed 1.21% lower on 5,055,200 shares. The brief found no reason for that decline.
3. COMPANY PROFILE
GE HealthCare develops, manufactures and markets medical products, services and digital solutions for diagnosis, treatment and monitoring. It reports four segments: Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics. Market capitalisation is $34.49bn, the forward P/E is 13.9 and the dividend yield is 0.22%. The peer group in the Health Care Equipment industry includes Medtronic, Abbott, Intuitive Surgical, Boston Scientific, Stryker and Dexcom.
On October 5 the company announced a $945m cash purchase of SOFIE Biosciences, a US PET radiopharmaceutical contract manufacturer. It is expected to close in the first half of 2027, subject to regulatory approvals. Management expects it to add to revenue growth, adjusted EBIT margin and adjusted EPS in the first full year of ownership (Yahoo Finance, around October 6). The deal did not drive the October 28 move.
4. DEEP DIVE ANALYSIS
Do fundamentals justify the move? The quarter delivered a profit beat, a margin gain of 180 bp, and a raise to the EPS range. The midpoint of adjusted EPS guidance moved to $5.00 from $4.90. Organic growth guidance narrowed upward to about 4%, and orders of 4.0% organic growth with a 1.03x book-to-bill support the revenue outlook. Given the forward P/E of 13.9, the market rewarded a visible improvement in earnings quality.
Cash quality. The $55m tariff refund sits inside both cash flow figures, so underlying free cash flow was lower than the reported $793m.
Comparable episodes. After the second quarter, Mizuho raised its target to $85 from $80 on 11% organic order growth and an adjusted EPS beat ($1.13 against $1.04), per Investing.com on July 30. The brief does not give the stock's move that day. Orders have since slowed to 4.0% organic growth from 11%, although that comparison uses different sources. In the third quarter of 2024, the company raised only the low end of its margin and EPS guidance on 1% revenue growth (SEC 8-K, October 30, 2024), a smaller raise on weaker sales than this year's.
Analyst reaction.
| Broker | New target | Prior | Source |
|---|---|---|---|
| Stifel (Buy) | $90 | $80 | Investing.com |
| BTIG | $83 | $75 | MarketScreener |
| Evercore ISI | $84 | $83 | MarketScreener |
MarketScreener put the consensus average target at $82.70 across 22 analysts, about 9% above the close of $75.82.
Peers. On the session, Medtronic rose 0.88%, Stryker 0.86%, Dexcom 0.08%, Abbott fell 0.45%, Intuitive Surgical 0.38% and Boston Scientific 5.84%, while the S&P 500 gained 0.28%. The mixed peer picture indicates the GEHC move was company-specific. The brief offers no explanation of the peer moves.
Bull case. Margin expansion, rising guidance, falling tariff drag, a dividend increase and a stock that remains 15.4% below its January high leave room for rerating if growth holds near 4%.
Bear case. Order growth of 4.0% is modest, the cash flow includes a one-off, and Citi's preview flagged inflation, input costs, the Middle East conflict and China as areas of concern. Mizuho said in July that China's outlook had improved slightly but that a recovery was too early to call.
5. TECHNICAL SNAPSHOT
The close of $75.82 sits above the 50-day average of $68.33 and the 200-day average of $69.83, so the stock has regained both after trading below them in recent weeks. It remains well below the 52-week high of $89.59 and 29.2% above the 52-week low of $58.68. The shares are up 16.05% over 20 sessions. Volume of 9,569,300 was 2.86 times the 50-session average, which shows broad participation. The nearest support is the prior close of $71.11, with $71.98 just above it. The session high of $77.88 is the nearest visible resistance in this window, although the latest close is the highest in the table.
6. RISK FACTORS
- Underlying cash conversion is weaker than the headline because of the $55m tariff refund.
- Order growth of 4.0% leaves less room if demand softens.
- Citi's preview flagged inflation, input costs, the Middle East conflict and China as pressure points.
- SOFIE Biosciences closing is expected in the first half of 2027 and depends on regulatory approvals.
- The stock gained 16.05% in 20 sessions, which raises the chance of profit-taking.
- No further earnings date appears in the sources, and the brief found no other dated catalysts.
7. ACTIONABLE OUTLOOK
Short term (1-2 weeks): The gap higher on heavy volume and the target raises provide support. The $71.11 close is the nearest floor, and $77.88 is the level to clear for further gains. Inference: following a rally of this size, some consolidation is likely.
Medium term (1-3 months): Direction depends on whether orders hold near 4% organic growth, whether margins stay near 16% and whether free cash flow reaches the guided level above $1.6bn. The consensus target of $82.70 gives a reference point, with Stifel's $90 at the high end of the brokers cited.
Long term: The thesis has improved at the margin because earnings guidance rose and the margin trend is positive. The SOFIE deal adds a radiopharmaceutical manufacturing business in 2027. The core questions of China and order momentum remain open. This is analysis only and not personal financial advice.